Business Wire

IQM

9.12.2021 17:02:06 CET | Business Wire | Press release

Share
IQM: A New Super-cooled Microwave Source Boosts the Scale-up of Quantum Computers

In a new work published in Nature Electronics, researchers in Finland have developed a circuit that produces the high-quality microwave signals required to control quantum computers while operating at temperatures near absolute zero. This is a key step towards moving the control system closer to the quantum processor, which may make it possible to greatly increase the number of qubits in the processor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005593/en/

One of the factors limiting the size of quantum computers is the mechanism used to control the qubits in quantum processors. This is normally accomplished using a series of microwave pulses, and because quantum processors operate at temperatures near absolute zero, the control pulses are normally brought into the cooled environment via broadband cables from room temperature.

As the number of qubits grows, so does the number of cables needed. This limits the potential size of a quantum processor, because the refrigerators cooling the qubits would have to become larger to accommodate more and more cables while also working harder to cool them down – ultimately a losing proposition.

A research consortium including Aalto University , VTT Technical Research Centre of Finland , and IQM Quantum Computers has now developed a key component of the solution to this conundrum. ‘We have built a precise microwave source that works at the same extremely low temperature as the quantum processors, approximately -273 degrees,’ says the team leader Mikko Möttönen , Professor at Aalto University and VTT Technical Research Centre of Finland and a Co-Founder and Chief Scientist of IQM.

The new microwave source is an on-chip device that can be integrated with a quantum processor. Less than a millimetre in size, it potentially removes the need for high-frequency control cables connecting different temperatures. With this low-power, low-temperature microwave source, it may be possible to use smaller cryostats while still increasing the number of qubits in a processor.

‘Our device produces one hundred times more power than previous versions, which is enough to control qubits and carry out quantum logic operations,’ says Möttönen. ‘It produces a very precise sine wave, oscillating over a billion times per second. As a result, errors in qubits from the microwave source are very infrequent, which is important when implementing precise quantum logic operations.’

However, a continuous-wave microwave source, such as the one produced by this device, cannot be used as is to control qubits. First, the microwaves must be shaped into pulses. The team is currently developing methods to quickly switch the microwave source on and off.

Even without a switching solution to create pulses, an efficient, low-noise, low-temperature microwave source could be useful in a range of quantum technologies, such as quantum sensors.

‘In addition to quantum computers and sensors, the microwave source can act as a clock for other electronic devices. It can keep different devices in the same rhythm, allowing them to induce operations for several different qubits at the desired instant of time,’ explains Möttönen.

The theoretical analysis and the initial design were carried out by Juha Hassel and others at VTT. Hassel, who started this work at VTT, is currently the head of engineering and development at IQM Quantum Computers, Pan-European leader in quantum computers. The device was then built at VTT and operated by postdoctoral research Chengyu Yan and his colleagues at Aalto University using the OtaNano research infrastructure. Yan is currently an associate professor at Huazhong University of Science and Technology, China. The teams involved in this research are part of the Academy of Finland Centre of Excellence in Quantum Technology (QTF) and the Finnish Quantum Institute (InstituteQ).

Original research paper

Chengyu Yan, Juha Hassel, Visa Vesterinen, Jinli Zhang, Joni Ikonen, Leif Grönberg, Jan Goetz and Mikko Möttönen, A low-noise on-chip coherent microwave source , Nature Electronics, DOI:10.1038/s41928-021-00680-z (2021)

https://doi.org/10.1038/s41928-021-00680-z (link opens after embargo ceases)

Preprint available at any time: https://arxiv.org/pdf/2103.07617

More pictures in the material bank : https://materialbank.aalto.fi/l/sjcg87sHxFfR

About IQM Quantum Computers

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich and Espoo and employs over 130 people. More information: www.meetiqm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye